NCT00741988 - Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2012

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Ixabepilone

ixabepilone 30 mg/m2

DRUG

Carboplatin

carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.

DRUG

Bevacizumab

bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.

Trial Locations (13)

Center for Cancer and Blood Disorders, Bethesda

Peninsula Cancer Institute, Newport News

South Carolina Oncology Associates, Columbia

Spartanburg Regional Medical Center, Spartanburg

Gainsville Hematology Oncology Associates, Gainesville

Florida Cancer Specialists, Fort Myers

Tennessee Oncology, PLLC, Nashville

Consultants in Blood Disorders and Cancer, Louisville

Oncology Hematology Care, Cincinnati

Providence Medical Group, Terre Haute

Grand Rapids Clinical Oncology Program, Grand Rapids

Dr. Donald Berdeaux, Great Falls

Research Medical Center, Kansas City